Browsing Category
Pharma Industry News
4140 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Vanda Pharmaceuticals (VNDA) bets on GLP-1 adherence gap with new Nereus vomiting-prevention study
Vanda Pharmaceuticals has launched the Thetis study to test Nereus in GLP-1-related vomiting. Read what this means for obesity drug adherence and VNDA.
Why industry observers are watching Tenvie Therapeutics’ TNV262 biomarker readout in 2026
Tenvie Therapeutics’ TNV262 readout in 2026 could reshape obesity and cardiometabolic drug development. Read why markets are watching closely.
How the FDA meeting could redefine pelareorep’s registrational path in anal cancer
Could Oncolytics Biotech redefine pelareorep’s approval path in anal cancer? Read what the FDA meeting means for commercialization and investor sentiment.
QNCX: What does the reverse merger hunt at Quince Therapeutics mean for shareholders after the NEAT trial collapse?
Quince Therapeutics (Nasdaq: QNCX) has no pipeline and a September Nasdaq deadline. Here's what the reverse merger hunt actually means for retail investors watching this stock.
Avacta (AVCT) at AACR 2026: What the San Diego data presentations actually mean if you’re holding shares through the trial
Avacta Therapeutics (AIM: AVCT) is presenting two posters at AACR 2026 in San Diego. Here is what investors need to understand about conference data versus clinical trial readouts and which milestones actually move the stock.
Amgen (AMGN) stock in focus as subcutaneous TEPEZZA Phase 3 data strengthens thyroid eye disease franchise
Amgen’s Phase 3 subcutaneous TEPEZZA win could reshape thyroid eye disease treatment and competition. Read what it means for AMGN now.
Cipla Limited (NSE: CIPLA) secures FDA approval for generic nintedanib capsules, entering a $3.8bn U.S. pulmonary fibrosis market
Cipla wins FDA approval for generic nintedanib capsules for IPF, targeting Boehringer Ingelheim's $3.76B Ofev market. Here's what the launch means for investors. Read more.
Regeneron Pharmaceuticals (NASDAQ: REGN) bets on data scale as TriNetX deal opens access to 300 million patient records
Regeneron is pairing with TriNetX to expand its health data reach and AI drug discovery ambitions. Read what the deal could change next.
Can Matinas BioPharma (MTNB) avoid delisting while trying to salvage MAT2203?
Matinas BioPharma faces NYSE American non-compliance over equity levels. Read what it means for MTNB, MAT2203, funding options, and delisting risk.
Algorae Pharmaceuticals (ASX: 1AI) raises A$4m to fund dual commercial and AI drug discovery growth strategy
Algorae Pharmaceuticals (ASX: 1AI) raises A$3.99m to scale AlgoraeRx commercial portfolio and advance AlgoraeOS AI drug pipeline. Read the full strategic analysis.